Literature DB >> 34252305

MIC Values of Iclaprim and Lefamulin against Mycobacterium abscessus Complex.

Ka Lip Chew1, Sophie Octavia2, Siang Fei Yeoh3, Jeanette W P Teo1.   

Abstract

Entities:  

Keywords:  Mycobacterium abscessus complex; broth microdilution; iclaprim; lefamulin

Mesh：

Substances：

Year:  2021        PMID： 34252305      PMCID： PMC8448135          DOI： 10.1128/AAC.00619-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

1.  Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Authors:  Rodrigo E Mendes; Susanne Paukner; Timothy B Doyle; Steven P Gelone; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens.

Authors:  Ka Lip Chew; Sophie Octavia; Joelle Go; Sally Ng; Yit Er Tang; Patsy Soh; Joy Yong; Roland Jureen; Raymond Tzer Pin Lin; Siang Fei Yeoh; Jeanette Teo
Journal:  J Antimicrob Chemother       Date:  2021-03-12       Impact factor: 5.790

3.  A multilocus sequence typing scheme for Mycobacterium abscessus complex (MAB-multilocus sequence typing) using whole-genome sequencing data.

Authors:  Michelle Wuzinski; Aneta K Bak; Aaron Petkau; Walter H B Demczuk; Hafid Soualhine; Meenu Kaushal Sharma
Journal:  Int J Mycobacteriol       Date:  2019 Jul-Sep

4.  In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections.

Authors:  Stephanie Noviello; Sophie Magnet; Stephen Hawser; David B Huang
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.

Authors:  R J Wallace; K Wiss; M B Bushby; D C Hollowell
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

Review 6.  Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.

Authors:  George G Zhanel; Christina Deng; Sheryl Zelenitsky; Courtney K Lawrence; Heather J Adam; Alyssa Golden; Liam Berry; Frank Schweizer; Michael A Zhanel; Neal Irfan; Denice Bay; Philippe Lagacé-Wiens; Andrew Walkty; Lionel Mandell; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2021-02       Impact factor: 9.546

7.  Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.

Authors:  David B Huang; Cedric Charrier; Stephen Hawser
Journal:  Diagn Microbiol Infect Dis       Date:  2020-02-05       Impact factor: 2.803

Review 8.  Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin Resistant Staphylococcus aureus.

Authors:  Sungmin Kiem; Jerome J Schentag
Journal:  Infect Chemother       Date:  2014-12-29

9.  Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  Wolfgang W Wicha; Dirk B Strickmann; Susanne Paukner
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.